Genetic screening for glucocorticoid-remediable aldosteronism (GRA): Experience of three clinical centres in Poland

Journal of Applied Genetics

Volumn 46, Issue 3, 2005, Pages 329-332

  Adler, Grazyna ^a   Widecka, Krystyna ^a   Pȩczkowska, Mariola ^b   Dobrucki, Tomasz ^b   Placha, Grzegorz ^c   Drozd, Radosław ^a   Parczewski, Miłosz ^a   Januszewicz, Andrzej ^b   Gaciong, Zbigniew ^c   Ciechanowicz, Andrzej ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Chimaeric gene; Genetic screening; Glucocorticoid remediable aldosteronism (GRA); Hypertension; PCR

Indexed keywords

ALDOSTERONE SYNTHASE; STEROID 11BETA MONOOXYGENASE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CHIMERA; CLINICAL TRIAL; CROSSING OVER; GENETIC SCREENING; GENETICS; GENOTYPE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MULTICENTER STUDY; POLAND; PROMOTER REGION;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ALDOSTERONE SYNTHASE; CHIMERA; CROSSING OVER, GENETIC; GENETIC SCREENING; GENOTYPE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; POLAND; PROMOTER REGIONS (GENETICS); STEROID 11-BETA-HYDROXYLASE;

EID: 24044492590     PISSN: 12341983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ciechanowicz A, Widecka K, Drozd R, Adler G, Cyryłowski L, Czekalski S, 2001. Lack of association between Gly460Trp polymorphism of alpha-adducin gene and salt sensitivity of blood pressure in Polish hypertensives. Kidney Blood Press Res 24: 201-206.
2. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. 2000. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863-1867.
3. Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS, 2001. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 15: 173-176.
4. Ignatowska-Świtalska H, Chodakowska J, Januszewicz W, Fełtynowski T, Adamczyk M, Lewandowski J, 1997. Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. J Hum Hypertens 11: 373-378.
5. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD, 1995. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 207: 565-571.
6. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM, 1992. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355: 262-265.
7. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG, 1998. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31: 445-450.
8. Litchtfield WR, Coolidge C, Silva P, Lifton RP, Fallo F, Williams GH, Dluhy RG, 1997. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 82: 1507-1510.
9. Litwin M, Tysarowska A, Malinowska M, Ciechanowicz A, Malunowicz E, Adler G, et al. 2002. Familial hyperaldosteronism type I: biochemical and molecular diagnosis in patient and normotensive family member. Pediatr Nephrol 17: C90.
10. MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC, et al. 1998. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 83: 4328-4331.
11. Mulatero P, Di Cella SM, Williams TA, Milan A, Mengozzi G, Chiandussi L, et al. 2002. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 87: 3187-3191.
12. Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, et al. 1998. Diagnosis of glucocorticoid remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 83: 2573-2575.
13. Prejbisz A, Postuła M, Cybulska I, Dobrucki T, Kabat M, Peczkowska M, et al. 2003. Biochemical investigations and clinical symptomatology in diagnostics and form differentiation of primary hyperaldosteronism. Kardiol Pol 58: 17-26.
14. Sutherland DJA, Ruse JL, Laidlaw JC, 1966. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95: 1109-1119.
15. Wyckoff JA, Seely EW, Hurwitz S, Anderson BF, Lifton RP, Dluhy RG, 2000. Glucocorticoid- remediable aldosteronism and pregnancy. Hypertension 35: 668-672.